Twenty-six modules, eight credits and no patient outcome: what British Columbia's free opioid agonist course actually certifies

A free course is the easiest object in this field to describe wrongly, because the free part is usually one component of something larger. That is the case here. Health Canada rescinded the federal exemption requirement for prescribing methadone in May 2018. What the centre claims of itself is narrower than the history usually told around it: in June 2017 the BC Centre on Substance Use became responsible for the province's education and training pathway for prescribing opioid agonist treatment, while the colleges continue to regulate the professionals. The pathway has three parts. Only the first one is free, open and reachable from outside the province.

The shape of the object

There are two online courses, and they are not the same size. The prescriber course has 26 modules across four streams; the nursing course has an estimated 14 to 16 hours and a module count that depends on which of the two builders you read. Thirty is the centre's figure. The university's page for the same course says the stream "is divided into 31 modules" and then lists 31 titles; the extra one is extended-release buprenorphine, added with the recent expansion of nursing scope of practice. Two organisations that built one course together publish two different sizes for it, and nothing on either page reconciles the two. Reading either page on its own also yields a module count that is wrong for the programme as a whole.

One practical note from checking the links rather than the prose: on 20 August 2026 the "Register now" link for the nursing course, published on two BCCSU pages, returned a 404 page at UBC CPD, while the prescriber course link resolved normally. That does not establish that the nursing course has gone; it establishes that the published route to it did not work on that date. A working route exists: the university's prescriber page carries a link to the same nursing course under a different address ending, and that one returned 200. What is out of date is the address the centre published, not the catalogue entry.

Certificate, credits, permission

These are commonly collapsed into one another, and here they are formally distinct. The platform issues a Certificate of Completion. The colleges issue credits, up to 8.0 Royal College Section 3 hours or 8.0 Mainpro+ credits for prescribers, 14.0 Canadian Nurses Association credits for nurses; these are Canadian systems, and the pages say nothing about recognition elsewhere. Authorisation to prescribe is a third document, the BCCSU Proof of Completion letter, and it requires the workbook and an in-person preceptorship with an approved preceptor. That letter covers the oral pathways only; the injectable route ends in a different instrument, an iOAT Collaborative Prescribing Agreement that the centre issues, the provincial ministry approves and the prescriber returns to the centre before injectable medications are activated in the provincial dispensing network.

What the programme says of itself belongs here too, because a sceptical account that leaves it out inverts the object. Its own annual report puts the claim on its front pages: POATSP is the only training pathway in the province by which physicians and nurse practitioners can prescribe opioid agonist treatment, injectable treatment included. The optionality is correspondingly narrow. Physicians and nurse practitioners are not required to complete the pathway in order to prescribe buprenorphine/naloxone, where completion is "strongly encouraged"; for methadone it is compulsory in substance, because under the College of Physicians and Surgeons of BC practice standard on prescribing methadone a registrant without a section 56(1) exemption, or one who has not prescribed methadone within the last three years, must complete the appropriate education and training through the centre.

What gets counted

The 2024/25 report states that its programme statistics cover activities completed in that fiscal year unless noted, and gives 721 completions and 222 preceptors. The front panel's 1,854 and 11,643 carry no period label, so the two sets should not be added or read as the same quantity. The prescriber curve, 773 to 2,029, comes with its own footnote: a prescriber is counted as a clinician with at least one dispensation from a prescription they wrote in a given month, an indicator the report says does not capture everyone who wrote an opioid agonist prescription. That footnote is the most candid sentence in the document. The curve is also not monotonic: the previous annual report gives 2,050 prescribers as of April 2024, against 2,029 as of December 2024 here, so the movement from 773 is a net rise across the whole period and not a continuous climb.

What is known about effect

An evaluation of the programme exists, and it is linked from the same nursing pathway page that supplies the 30 modules, the 40 hours and the 10 seats: "POATSP for RN and RPN OUD CP Education and Training Pathway: Second Evaluation", BCCSU, November 2023. It pools three surveys – the post-course evaluation survey every learner must complete to obtain a certificate, a targeted survey of nurses who finished the whole pathway, and a survey of preceptors – and every outcome in it is a perception. Among course respondents, 71.9% agreed or strongly agreed that the online course enabled them to meet its stated learning objectives, and 73.5% were fairly or very confident that it had prepared them for the expanded scope of practice; among nurse prescribers, 93.3% were satisfied with the quality of the pathway and 24.5% found the online course too long. Not one patient outcome is measured anywhere in it. The word "Second" in the title says there was a first. No equivalent evaluation of the physician and nurse practitioner pathway was found on the pages checked, and neither the evaluation nor the programme is indexed in PubMed. Evidence that reaches patients sits one level out and is worth reading for what it does and does not measure. An interrupted time series across eight provinces (Sud et al., BMC Health Services Research, 2024) found prescriber growth everywhere between June 2017 and May 2019, the fastest-growing province growing 4.5 times more than the slowest, and effects of the 2018 federal exemption removal ranging from clearly positive to possibly negative; its outcome is the number of prescribers, not patients treated or retained. A population cohort of 265,410 treatment episodes in British Columbia from 2014 to 2021 (Guerra-Alejos et al., Addiction, 2024) reported that prescribers appeared to start patients above guideline doses (methadone in 53% to 66% of episodes) and to maintain higher doses, with take-home allowances beyond guideline length increasing. Its conclusion adds that clients were titrated more rapidly, and its findings section is narrower than that: titration intervals were consistent with the guideline for buprenorphine/naloxone and shorter than recommended only for methadone and slow-release oral morphine. This account follows the findings section rather than the conclusion. All of it is measured against the 2017 guideline rather than the 2023 edition now taught, and the authors read the higher dosing as adaptation to a fentanyl supply rather than as error. For scale, the BC Coroners Service recorded 2,253 unregulated drug toxicity deaths in the province in 2024, 13% fewer than in 2023. Nothing published connects that figure to the training in either direction, and it should not be used to praise or condemn the course.

What it is good for

Taken for what it is, this is a genuinely useful free resource: a structured, current, accredited curriculum on inducting and maintaining patients on buprenorphine/naloxone, extended-release buprenorphine, methadone, slow-release oral morphine and injectable treatment, written by the body that writes the province's guideline, open to a clinician anywhere with an account and no fee – no country restriction is stated, although the audience the page names is health care professionals in British Columbia. What it certifies is that a clinician has worked through it. Whether the patients of those clinicians stay in treatment longer or die less often is a question this programme, like most continuing education, does not ask about itself.